SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit for $75 million

Company Overview - SERB Pharmaceuticals has acquired RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions Inc. for approximately $75 million, with an additional $5 million milestone payment [2] - The acquisition strengthens SERB's position as a leading provider of medical countermeasures for chemical, biological, radiological, and nuclear threats [4] - SERB has a broad portfolio of antidotes and preventive medicines, enhancing opportunities to partner with governments, militaries, NGOs, and emergency preparedness agencies globally [4][7] Product Details - RSDL® is a medical device designed to remove or neutralize chemical warfare agents from the skin, including tabun, sarin, soman, and mustard gas [1][8] - It is the only FDA-cleared device backed by 20 years of clinical data, capable of performing its function in one step [1] - Over 15 million packets of RSDL® have been sold in more than 30 countries [1] Operational Aspects - As part of the acquisition, SERB will operate the leased manufacturing facility in Hattiesburg, Mississippi, and retain several employees supporting the RSDL® product [2] - RSDL® was initially developed by Defence Research and Development Canada to prepare Canadian forces for chemical warfare attacks and has received multiple international approvals [4]